Search results
Pneumococcal conjugate vaccine is a pneumococcal vaccine made with the conjugate vaccine method and used to protect infants, young children, and adults against disease caused by the bacterium Streptococcus pneumoniae (pneumococcus).
PCV7: First-generation conjugate vaccine manufactured by Pfizer which offers protection against 7 pneumococcal serotypes. It was developed for Europe and the U.S. markets and is being replaced by the 10-valent and 13-valent vaccine formulations. PCV10: 10-valent vaccine, manufactured by GlaxoSmithKline (GSK) offering protection against.
GlaxoSmithKline (GSK) today received European Commission authorisation for Synflorix™, a paediatric pneumococcal vaccine to protect against life-threatening diseases such as meningitis and bacteraemic pneumonia, as well as middle ear infections.
FDA licensed the first pneumococcal conjugate vaccine (PCV7) in 2000. A large clinical trial showed PCV7 reduced invasive disease caused by vaccine serotypes by 97%. Compared to unvaccinated children, children who received PCV7:
17 lis 2021 · 1. Introduction. Streptococcus pneumoniae (Spn, the pneumococcus) is a frequent component of the human nasopharyngeal microbiota, but it is also an important pathogen, especially in children under five years of age and the elderly, as it is responsible for several hospitalizations and deaths [1, 2].
The last vaccine to be developed, the 13-valent pneumococcal conjugate vaccine (PCV13), contains the seven serotypes in PCV7, five additional serotypes from PPSV23, and a new serotype not contained in PPSV23 or PCV7.
1 wrz 2021 · This document summarizes current technical and programmatic information on WHO prequalified PCV products to facilitate informed country choices for PCV introduction or product switch for childhood immunization programmes.
